Tocilizumab

drugbox
type = mab


source = Humanized
target = IL-6 receptor
CAS_number =
ATC_prefix = L04
ATC_suffix = AC07
PubChem =
DrugBank =
chemical_formula =
molecular_weight =
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category =
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration =

Tocilizumab (under development by Roche and Chugai under the trade name Actemra) is a humanized monoclonal antibody against IL-6R (interleukin-6 receptor) used as an immunosuppressive drug.

As of 2008, it is currently under regulatory review by the United States Food and Drug Administration (US FDA) and the European Medicines Agency (EMA).

It has been proposed for use in Castleman's disease.cite journal |author=Matsuyama M, Suzuki T, Tsuboi H, "et al" |title=Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease |journal=Intern. Med. |volume=46 |issue=11 |pages=771–4 |year=2007 |pmid=17541233 |doi= |url=http://joi.jlc.jst.go.jp/JST.JSTAGE/internalmedicine/46.6262?from=PubMed]

References